Depressed Platelet Status in an Elderly Patient With Hemorrhagic Stroke After Thrombolysis for Acute Myocardial Infarction

Victor L. Serebruany, MD, PhD; Paul A. Gurbel, MD; Andrew R. Shustov, MD; Margaret R. Dalesandro, PhD; Cindy I. Gumbs, BS; Laura B. Grabletz, BS; Raymond D. Bahr, MD; E. Magnus Ohman, MD; Eric J. Topol, MD; for the GUSTO-III Investigators

Background—Impaired platelet function has been reported in acute myocardial infarction (AMI) and stroke. However, prospective data on the changes of platelet status in patients before the occurrence of hemorrhagic stroke after thrombolytic therapy are unavailable.

Case Description—An 86-year-old male patient was among the 23 AMI patients enrolled in the platelet study for the GUSTO-III trial. He received 325 mg of aspirin daily for at least 6 years, suffered an AMI, and was successfully reperfused with alteplase, but after 44 hours developed a large hemorrhagic stroke resulting in paraplegia. Platelet aggregation and receptor expression were measured by flow cytometry and ELISA before thrombolysis and at 3, 6, 12, and 24 hours thereafter. The percentage of platelet aggregation was lower in the stroke patient at every time point when induced by 5 μmol/L of ADP, by 10 μmol/L of ADP, and by thrombin than in the rest of the AMI group. Ristocetin and collagen-induced aggregability were within the group range. Decreased platelet glycoprotein Ib, IIb, IIIa, and IIb/IIIa and vitronectin receptor expression were observed in the stroke patient. No other differences in p24 (CD9), very late antigen-2, P-selectin, and platelet/endothelial cell adhesion molecule-1 expression were determined.

Conclusions—Profound depression of platelet status preceded the occurrence of hemorrhagic stroke in an elderly long-term aspirin user treated with thrombolytic therapy. Initial “exhausted” platelets may be responsible for the increased risk for hemorrhagic stroke after coronary thrombolysis. (Stroke. 1998;29:235-238.)

Key Words: hemorrhagic stroke ■ myocardial infarction ■ platelets ■ thrombolysis

Platelets have been implicated as important components in the natural history of acute myocardial infarction (AMI) and stroke. Thrombolytic agents remain the cornerstone of treatment for patients with AMI, whereas intracerebral bleeding is the most serious complication of their use. There is substantial evidence from in vitro and animal studies that impaired platelet function occurs after thrombolytic therapy and may play a role in the occurrence of intracranial hemorrhage. However, prospective dynamic data on the platelet status in patients before the occurrence of hemorrhagic stroke after thrombolytic therapy for AMI are unavailable.

We describe an elderly patient with an AMI who was enrolled in the GUSTO-III trial and underwent serial measurements of platelet aggregability, soluble receptor levels, and major surface receptor expression who later developed an intracerebral hemorrhage.

Case Report
An 86-year-old man with no prior cardiac history was admitted to the emergency department of St Agnes Hospital with 2.5 hours of left arm pain and chest discomfort. Blood pressure was 129/75 mm Hg, and pulse was 85 beats per minute. The physical examination was unremarkable. Past medical history was relevant for a hemicolectomy for villous adenoma. There was no history of bleeding diathesis or tobacco or alcohol use. The patient had received 325 mg of aspirin daily for the last 6 years. There were no other concomitant medications. The electrocardiogram demonstrated normal sinus rhythm with Q waves in leads V1 through V3 and ST segment elevation in leads V1 through V4, indicating an acute anteroseptal myocardial infarction. The white blood cell count was 8400/mL, platelet count was 196 000/mL, and the hematocrit was 44.5%. The blood urea nitrogen was 14 mg/dL, and creatinine was 1.1 mg/dL. The activated partial thromboplastin time was 34 seconds.

The patient was treated with 325 mg of aspirin and 5000 U of intravenous heparin, followed by a continuous infusion of heparin as recommended in the GUSTO-III protocol. The patient was randomized to treatment with 100 mg of alteplase (15 mg bolus followed by 85 mg infusion over 90 minutes).
Platelet characteristics were severely depressed in this patient compared with control subjects and the AMI group. Platelet aggregation in response to ADP (both 5 and 10 \( \mu \text{mol/L} \)) and thrombin were the lowest among the AMI patients. Collagen- and ristocetin-induced platelet aggregability were diminished, but within the group range. The lowest surface receptor expression among the AMI group was observed for platelet glycoproteins Ib (↓ 64%), IIb (↓ 25%), IIa (↓ 39%), IIb/IIIa (↓ 72%), and the vitronectin receptor (↓ 55%). The patient with intracerebral hemorrhage also had lower levels of soluble substances indicative of platelet activation (P-selectin and platelet–endothelial cell adhesion molecule [PECAM]-1) before thrombolysis. Compared with baseline, we observed some changes of the platelet status after thrombolytic therapy. The patterns of these changes were similar in the patient with the hemorrhagic stroke compared with the rest of AMI group. Early in thrombolysis (3 to 6 hours), we observed minor reductions of platelet aggregation and receptor expression together with a substantial increase of soluble P-selectin and PECAM-1 plasma concentrations. Later in thrombolysis (12 to 24 hours), we found a slight elevation of platelet aggregability, an increase in specific expression of glycoprotein IIb/IIIa, very late antigen-2, and PECAM-1 with no further changes of soluble P-selectin and PECAM-1. The dynamics of these receptors over 24 hours are shown in the figure.

### Baseline Platelet Status in Patient With Stroke Compared With the Rest of AMI Population and Healthy Controls*

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control Subjects (n=10)</th>
<th>AMI Patients (n=22)</th>
<th>Patients With Stroke</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aggregation, %</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. ADP 5 ( \mu \text{mol/L} )</td>
<td>(52.0\pm6.7) (39-61)</td>
<td>(66.3\pm11.4) (47-82)</td>
<td>42</td>
</tr>
<tr>
<td>2. ADP 10 ( \mu \text{mol/L} )</td>
<td>(59.2\pm7.2) (45-67)</td>
<td>(73.8\pm12.0) (54-90)</td>
<td>49</td>
</tr>
<tr>
<td>3. Collagen 1 mg/mL</td>
<td>(62.2\pm5.9) (58-74)</td>
<td>(64.7\pm6.9) (49-72)</td>
<td>66</td>
</tr>
<tr>
<td>4. Thrombin 1 mg/mL</td>
<td>(60.5\pm6.9) (49-71)</td>
<td>(75.8\pm10.9) (59-94)</td>
<td>54</td>
</tr>
<tr>
<td>5. Ristocetin 1.25 mg/mL</td>
<td>(71.3\pm7.4) (59-64)</td>
<td>(92.5\pm7.8) (72-100)</td>
<td>84</td>
</tr>
<tr>
<td><strong>Surface Receptor Expression, log fluorescence</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. CD9 ((\beta 24))</td>
<td>(41.07\pm11.40) (20.37-58.11)</td>
<td>(55.12\pm17.23) (18.12-79.04)</td>
<td>51.44</td>
</tr>
<tr>
<td>2. GP Ib</td>
<td>(133.76\pm7.96) (124.43-148.21)</td>
<td>(103.62\pm29.89) (39.28-161.02)</td>
<td>37.18</td>
</tr>
<tr>
<td>3. GP IIb</td>
<td>(37.19\pm1.73) (34.28-40.03)</td>
<td>(28.42\pm2.52) (24.44-33.21)</td>
<td>22.76</td>
</tr>
<tr>
<td>4. GP IIIa</td>
<td>(320.29\pm25.20) (278.90-361.00)</td>
<td>(326.97\pm51.78) (211.56-418.22)</td>
<td>201.06</td>
</tr>
<tr>
<td>5. GP IIb/IIIa</td>
<td>(53.02\pm6.95) (40.29-61.27)</td>
<td>(59.24\pm16.3) (18.12-79.04)</td>
<td>16.39</td>
</tr>
<tr>
<td>6. VLA-2</td>
<td>(41.36\pm2.14) (38.78-45.13)</td>
<td>(40.18\pm4.66) (33.03-51.19)</td>
<td>45.18</td>
</tr>
<tr>
<td>7. P-Selectin</td>
<td>(25.11\pm2.56) (20.67-29.95)</td>
<td>(31.54\pm4.96) (22.18-40.04)</td>
<td>27.90</td>
</tr>
<tr>
<td>8. PECAM-1</td>
<td>(44.47\pm3.75) (38.18-49.14)</td>
<td>(56.84\pm17.69) (26.28-81.07)</td>
<td>61.12</td>
</tr>
<tr>
<td>9. Vitronectin</td>
<td>(59.76\pm6.00) (44.96-65.05)</td>
<td>(60.16\pm25.56) (29.24-129.40)</td>
<td>27.15</td>
</tr>
<tr>
<td><strong>Soluble Receptors, ng/mL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. P-selectin</td>
<td>(10.24\pm1.07) (9.06-11.60)</td>
<td>(26.13\pm12.93) (10.35-57.24)</td>
<td>9.82</td>
</tr>
<tr>
<td>2. PECAM-1</td>
<td>(27.74\pm6.49) (20.29-36.80)</td>
<td>(35.19\pm9.66) (18.55-48.19)</td>
<td>19.20</td>
</tr>
</tbody>
</table>

*(AMI indicates acute myocardial infarction; GP, glycoprotein; VLA, very late antigen; and PECAM, platelet-endothelial cell adhesion molecule. Results are expressed as mean±SD. Ranges are given in parentheses.*
Discussion

The present report emphasizes the potential importance of baseline platelet characteristics in the pathogenesis of hemorrhagic stroke after thrombolytic therapy for AMI. We attempted to correlate antecedent platelet status by using conventional aggregometry, ELISA, and flow cytometry techniques, with an episode of hemorrhagic stroke in the oldest patient enrolled in the GUSTO-III platelet study.

The major complication of thrombolytic therapy is hemorrhagic stroke, which occurs in 1.2% to 1.9% of treated AMI patients. Platelets have been implicated in both ischemic and hemorrhagic stroke. However, all of these studies have been performed in the relatively late phases of acute stroke and could be confounded by the natural history of the disease and the effects of various concomitant medications. The prospective assessment of the platelet status in the controlled clinical trial provides us with a unique opportunity to characterize the patient’s platelets before the occurrence of stroke.

It should be noted that none of the measured platelet aggregation agonists, soluble antigens, or surface receptors served as a specific marker exclusively affected in the described patient. In contrast, we found a profound depression of multiple platelet-related characteristics. This finding leads us to an important observation. We can no longer hypothetically assume that platelets are necessarily systemically activated during the initial pre-reperfusion phase of AMI.

Another meaningful issue is the long-term use of relatively high doses of aspirin, which was documented in the described patient. However, there is no evidence that depressed platelet characteristics in this patient were directly related to the antecedent aspirin therapy.

This preliminary report also suggests that the adequate and timely assessment of platelet activity may be critical in assessing the risk for hemorrhagic stroke. Bleeding events after standard thrombolytic and/or antiplatelet therapy could be related to the decreased platelet characteristics in such patients. It is not clear whether we should uniformly use aggressive thrombolytic strategies without individual assessment of platelet status in AMI patients. Based on the present case, it is reasonable to speculate that the early bleeding complication observed after modern therapy could be, at least in part, related to depressed baseline platelet characteristics.

In conclusion, the ability to define patients at risk of hemorrhagic stroke after thrombolysis in AMI cannot be overstated. If platelets indeed are vital elements of the acute coronary and cerebrovascular events, then their characteristics could affect the response to thrombolytic therapy and clinical outcome. In our case, profound depression of platelet status preceded the occurrence of hemorrhagic stroke in an elderly patient who was successfully reperfused. Dysfunctional platelets may be responsible for the increased risk of provoking hemorrhagic stroke after thrombolysis. Further analysis of the baseline platelet status and its clinical significance during acute vascular syndromes remains to be determined.

Acknowledgments

This work was supported, in part, by Medtronic, Inc, and by Boehringer Mannheim GmbH. We are indebted to the staff of the emergency departments and critical care units of the St Agnes and the Union Memorial Hospitals. We would like to thank Kenneth A. Ault, MD, for his advice with the flow cytometry techniques and Barry S. Coller, MD, for his constructive comments and helpful suggestions on the manuscript.

References

Depressed Platelet Status in an Elderly Patient With Hemorrhagic Stroke After Thrombolysis for Acute Myocardial Infarction


Stroke. 1998;29:235-238
doi: 10.1161/01.STR.29.1.235
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1998 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/29/1/235

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/